Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cobimetinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ACTR3 | P61158 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cobimetinib SCHEMBL29839406 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL188704 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL29358284 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL29413366 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL1488831 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL29413464 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL1489148 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL30220897 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL1488436 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL189480 | 0.97 | MAP2K1 (0.95) | MAP2K1MAP2K2CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10326 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146289-A1 | ASSESSING AND TREATING MELANOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4743074-A1 | METHODS OF TREATING HEMATOLOGIC CANCER | Foghorn Therapeutics Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130891-A1 | PIM KINASE INHIBITOR IN COMBINATION WITH KRAS INHIBITOR | NINGBO NEWBAY TECH DEVELOPMENT CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | claimed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | claimed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |